ReviewPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2015
T cell engineering as therapy for cancer and HIV: our synthetic future.
Review in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- From concept to cure: The evolution of CAR-T cell therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- 3D Printing as a Strategy to Scale-Up Biohybrid Hydrogels for T Cell Manufacture.ACS applied materials & interfaces · 2024Article
- An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells.PloS one · 2021Article
- TGFβ biology in cancer progression and immunotherapy.Nature reviews. Clinical oncology · 2021Review
- Safety and Tolerability of Adoptive Cell Therapy in Cancer.Drug safety · 2019Review
- Optimized DNA electroporation for primary human T cell engineering.BMC biotechnology · 2018Article
- Current Status of Gene Engineering Cell Therapeutics.Frontiers in immunology · 2018Review
- INSPIIRED: A Pipeline for Quantitative Analysis of Sites of New DNA Integration in Cellular Genomes.Molecular therapy. Methods & clinical development · 2017Article
- Disruption or Excision of Provirus as an Approach to HIV Cure.AIDS patient care and STDs · 2016Article
- Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus.PLoS pathogens · 2016Article
- Pluripotent stem cells progressing to the clinic.Nature reviews. Molecular cell biology · 2016Review
- Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?Immunotherapy (Los Angeles, Calif.) · 2015Article
- The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
It is now well established that the immune system can control and eliminate cancer cells. Adoptive T cell transfer has the potential to overcome the significant limitations associated with vaccine-based strategies in patients who are often immune compromised. Application of the emerging discipline of synthetic biology to cancer, which combines elements of genetic engineering and molecular biology to create new biological structures with enhanced functionalities, is the subject of this overview. Various chimeric antigen receptor designs, manufacturing processes and study populations, among other variables, have been tested and reported in recent clinical trials. Many questions remain in the field of engineered T cells, but the encouraging response rates pave a wide road for future investigation into fields as diverse as cancer and chronic infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.